Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.03Last Year’s EPS
0.03Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -22.77%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant growth in revenue and EBITDA, expansion through acquisitions, and strong performance in clinical testing volumes and NGS revenue. However, there were challenges in the non-clinical sector, particularly in pharma and biotech spending. Despite these challenges, the company's strategic initiatives and market positioning in oncology provide a robust outlook.Company Guidance
During the NeoGenomics First Quarter 2025 Conference Call, the company provided updated guidance for the fiscal year 2025. NeoGenomics raised its full-year revenue guidance to a range of $747 million to $759 million, reflecting 13% to 15% growth, driven by strong clinical volume growth and the recent acquisition of Pathline. The company reaffirmed its adjusted EBITDA guidance of $55 million to $58 million. Key metrics highlighted included first-quarter revenue of $168 million, a 102% year-over-year increase in adjusted EBITDA to $7.1 million, and an 8% increase in clinical testing volumes. The acquisition of Pathline is expected to contribute $12 million to $14 million in revenue for 2025, with anticipated incremental revenue and cost synergies materializing in 2026 and beyond. The company also noted ongoing challenges in the non-clinical segment due to broader macroeconomic conditions but expressed confidence in offsetting these with strong clinical performance.Record Revenue and EBITDA Growth
NeoGenomics reported revenues of $168 million and adjusted EBITDA of $7.1 million for Q1 2025, marking a 100% improvement over the prior year and the seventh consecutive quarter of positive adjusted EBITDA.
Clinical Testing Volume Increase
Clinical testing volumes increased by 8% compared to the previous year, with a 3% increase in revenue per test.
NGS Revenue Growth
NGS revenue grew by 18% in Q1 2025, with five new NGS products accounting for 22% of total clinical revenue.
Pathline Acquisition
NeoGenomics acquired Pathline, expanding their capabilities in the Northeast, expected to contribute $12-14 million in revenue for 2025.
---
NEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 29, 2025 | $9.97 | $6.58 | -34.00% |
| Feb 18, 2025 | $14.42 | $12.40 | -14.01% |
| Nov 05, 2024 | $14.14 | $14.93 | +5.59% |
| Jul 29, 2024 | $14.64 | $17.27 | +17.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NeoGenomics (NEO) report earnings?
NeoGenomics (NEO) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is NeoGenomics (NEO) earnings time?
NeoGenomics (NEO) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NEO EPS forecast?
NEO EPS forecast for the fiscal quarter 2025 (Q2) is 0.03.
---
